On June 5 and 6, an FDA advisory panel voted in favor of modifying the current Risk Evaluation and Modification Strategy (REMS), for GlaxoSmithKline’s (GSK) Avandia (...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
43 readers recommended
On April 3, an FDA Advisory Committee voted an overwhelming 13-1 in favor of approving MannKind’s ultra-rapid-acting inhaled insulin Afrezza for type 1 diabetes. The...
47 readers recommended
A major need for the 79 million Americans with prediabetes…
42 readers recommended
On December 11, Orexigen announced the resubmission of its weight management drug Contrave (naltrexone/bupropion) to the FDA. The company has previously stated that it...
32 readers recommended
On April 29, Merck and Pfizer announced that they are entering a partnership to develop ertugliflozin for type 2 diabetes. Ertugliflozin is a sodium-glucose linked...
40 readers recommended
On April 15, the FDA approved GlaxoSmithKline’s once-weekly GLP-1 agonist Tanzeum (albiglutide) for type 2 diabetes, which makes it the second once-weekly GLP-1 agonist...
42 readers recommended
All about diabetic macular edema (DME) and three tips for avoiding it.
74 readers recommended
The top three things I’d like to see in 2014 – updates on CGM, mHealth, and combination therapy.
24 readers recommended
In May, Lexicon announced its results of LX4211, an SGLT-1/SGLT-2 inhibitor. The phase 2 trial finished its open-label, pioneer section, which showed a decrease in...
42 readers recommended
At the end of March, encouraging news about Takeda’s once-daily pill for type 2 diabetes, Nesina (alogliptin), circulated at the American College of Cardiology (ACC)...
34 readers recommended
Eli Lilly announced in October the submission of dulaglutide, its once-weekly GLP-1 receptor agonist for type 2 diabetes, in the US and Europe. This means a regulatory...
41 readers recommended
On January 21, Glooko and Joslin announced a partnership to develop a new web/mobile-based diabetes management platform. The system will combine a “Virtual Joslin”...
52 readers recommended
At the ADA meeting. Biodel, Latitude, and Xeris had notable announcements on their glucagon programs. First, Biodel demonstrated a prototype of its new glucagon rescue...
26 readers recommended
On April 24, Hyperion Therapeutics announced that it would acquire Andromeda Biotech. Andromeda is focused on the development of a first-in-class immune therapy for new...
45 readers recommended
Halozyme announced recently that Yale researchers have started a 20-patient artificial pancreas study (which is still recruiting) that will test the ability of...
30 readers recommended
Twitter summary: BI/Lilly launch Jardiance in the US, making it the 3 rd SGLT-2 inhibitor on the market; savings program for one-year free supply After its recent FDA...
48 readers recommended
The Future of Type 1 Diabetes – what challenges and promises lie ahead? Part two of our interview with David Panzirer and Dana Ball.
49 readers recommended
Twitter summary: @LillyDiabetes launches Trulicity in the US – first ready-to-use once-weekly GLP-1, available w/savings program for commercially insured On November 10...
38 readers recommended
Can a type 2 diabetes drug work for type 1? Will an experimental drug improve blood glucose and body weight?
35 readers recommended
Twitter summary: BI/Lilly’s #insulin glargine receives EU approval – “Abrasia” set to launch in mid-2015 as 1 st ever “biosimilar” insulin in Europe On September 10, Eli...